[Clinical Analysis of Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation].

Q4 Medicine 中国实验血液学杂志 Pub Date : 2024-08-01 DOI:10.19746/j.cnki.issn.1009-2137.2024.04.038

Lan-Xiang Liu, Jing Wang, Li Wang, Lin Liu, Xin Wang, Hong-Bin Zhang, Xiao-Qiong Tang, Yi-Ying Xiong

{"title":"[Clinical Analysis of Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation].","authors":"Lan-Xiang Liu, Jing Wang, Li Wang, Lin Liu, Xin Wang, Hong-Bin Zhang, Xiao-Qiong Tang, Yi-Ying Xiong","doi":"10.19746/j.cnki.issn.1009-2137.2024.04.038","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the risk factors of Epstein-Barr virus (EBV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its impact on survival.Methods: The clinical data of 347 patients who underwent their first allo-HSCT in our hospital from January 2014 to June 2021 were retrospectively analyzed. Patients were divided into EBV (n =114) and Non-EBV (n =233) groups according to whether they were infected with EBV. The incidence of EBV infection after allo-HSCT was calculated, and the risk factors of EBV infection were analyzed.Results: A total of 114(32.8%) patients presented EBV infection (all peripheral blood EBV-DNA were positive). EBV infection occurred in 88 patients within 100 days after transplantation, which accounted for 77.2% of all patients with EBV infection. 5 cases (1.44%) were confirmed as post-transplant lymphoproliferative disorder (PTLD). The median onset time of patients was 57(7-486) days after transplantation. Multivariate analysis showed that the use of ATG/ATG-F, occurrence of CMV viremia, and grade III-IV aGVHD were risk factors for EBV infection. Furthermore, compared to BUCY, the use of intensified preconditioning regimens containing FA/CA was significantly increased the risk of EBV infection.Conclusion: EBV infection is a common complication after allo-HSCT. Intensified preconditioning regimens, use of ATG/ATG-F, CMV viremia and grade III to IV aGVHD increase the risk of EBV infection after allo-HSCT.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze the risk factors of Epstein-Barr virus (EBV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its impact on survival.

Methods: The clinical data of 347 patients who underwent their first allo-HSCT in our hospital from January 2014 to June 2021 were retrospectively analyzed. Patients were divided into EBV (n =114) and Non-EBV (n =233) groups according to whether they were infected with EBV. The incidence of EBV infection after allo-HSCT was calculated, and the risk factors of EBV infection were analyzed.

Results: A total of 114(32.8%) patients presented EBV infection (all peripheral blood EBV-DNA were positive). EBV infection occurred in 88 patients within 100 days after transplantation, which accounted for 77.2% of all patients with EBV infection. 5 cases (1.44%) were confirmed as post-transplant lymphoproliferative disorder (PTLD). The median onset time of patients was 57(7-486) days after transplantation. Multivariate analysis showed that the use of ATG/ATG-F, occurrence of CMV viremia, and grade III-IV aGVHD were risk factors for EBV infection. Furthermore, compared to BUCY, the use of intensified preconditioning regimens containing FA/CA was significantly increased the risk of EBV infection.

Conclusion: EBV infection is a common complication after allo-HSCT. Intensified preconditioning regimens, use of ATG/ATG-F, CMV viremia and grade III to IV aGVHD increase the risk of EBV infection after allo-HSCT.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[同种异体造血干细胞移植后 Epstein-Barr 病毒感染的临床分析]。

摘要分析异基因造血干细胞移植（allo-HSCT）后EB病毒（Epstein-Barr virus，EBV）感染的风险因素及其对生存率的影响：回顾性分析2014年1月至2021年6月在我院接受首次异基因造血干细胞移植的347例患者的临床资料。根据患者是否感染 EBV，将其分为 EBV 组（n =114）和非 EBV 组（n =233）。计算了allo-HSCT后EBV感染的发生率，并分析了EBV感染的风险因素：结果：共有 114 例（32.8%）患者出现 EBV 感染（所有外周血 EBV-DNA 均为阳性）。移植后 100 天内发生 EBV 感染的患者有 88 例，占所有 EBV 感染患者的 77.2%。5例（1.44%）被确诊为移植后淋巴组织增生性疾病（PTLD）。患者的中位发病时间为移植后57（7-486）天。多变量分析显示，使用ATG/ATG-F、出现CMV病毒血症和III-IV级aGVHD是EBV感染的危险因素。此外，与BUCY相比，使用含有FA/CA的强化预处理方案会显著增加EBV感染的风险：结论：EBV感染是allo-HSCT后常见的并发症。结论：EBV感染是allo-HSCT术后常见的并发症，强化预处理方案、ATG/ATG-F的使用、CMV病毒血症和III至IV级allo-HSCT会增加EBV感染的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊